一分钟看懂
这是一项关于前列腺癌的不适用研究，登记的药物或干预包括TULSA-PRO，当前状态为已暂停。登记地点显示中国Bethesda有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
TULSA-PRO · 不适用
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- National Institutes of Health Clinical Center · Bethesda
公开的入选条件
- Subjects must have prostate cancer amenable for ultrasound ablation defined as:
- * diagnosed by transrectal ultrasound-guided prostate biopsy via standard 12 core biopsy and targeted biopsy of any MRI-visible or tracked lesions; pathological diagnosis must be confirmed by Laboratory of Pathology, NCI;
- * Gleason Score \<= 7;
- * MRI-visible or MRI-tracked prostate cancer. This includes prostate cancer found on targeted biopsy of MRI-visible or MRI-tracked lesion. Histologically positive standard biopsy cores of Grade Group \>= 2 prostate cancer must be from an area overlying or with
- * organ confined clinical T1c or clinical T2a prostate cancer that is visualized on MRI. Note: Participants after prostate cancer treatment with local recurrence or residual tumor which is visible on MRI are eligible.
- * PSA \< 20 ng/ml or PSA \>20 with a PSA density \<0.15.
- * Adults (\>= 18 years of age)
- * Participants must have adequate organ and marrow function as defined below:
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT04808427；登记信息更新于 2026-09-16。